CLAY B SIEGALL
CIK 1167496 · President and CEO · last filed 2026-07-27
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$24.41M
Companies
8
Total Filings
211
Lifetime Open-Market Net
-$226.50M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMNM | President and CEO | 870,704 | $25.06 | $21.82M | $6.76M | 11 | 2026-07-27 |
| STTK | Director | 318,608 | $7.92 | $2.52M | $250.0K | 7 | 2026-06-11 |
| Tourmaline Bio, Inc. (TRML) Delisted | Director | — | $47.98 | — | $0 | 4 | 2025-10-28 |
| Seagen Inc. (SGEN) Delisted | President & CEO | 676,653 | $228.74 | $154.78M | -$229.11M | 168 | 2022-05-13 |
| NRIX | Director | — | $24.69 | — | $0 | 2 | 2022-05-06 |
| RARE | Director | 2,550 | $25.81 | $65.8K | -$2.97M | 9 | 2020-08-11 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Director | 31,714 | — | — | -$1.44M | 7 | 2019-05-28 |
| SYNLOGIC, INC. (MIRN) Delisted | Director | — | — | — | $0 | 1 | 2016-09-06 |
Recent Filings · Page 2 of 22
211 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-07-16 | STTK | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | Tourmaline Bio, Inc. (TRML) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-26 | IMNM | Buy (P) | +137,100 | $999.5K | EDGAR |
| 2025-02-03 | IMNM | Buy (P) | +150,000 | $1.16M | EDGAR |
| 2024-11-25 | IMNM | Buy (P) | +100,000 | $962.2K | EDGAR |
| 2024-08-13 | IMNM | Grant (A) | — | $0 | EDGAR |
| 2024-06-21 | STTK | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | Tourmaline Bio, Inc. (TRML) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-21 | IMNM | Buy (P) | +100,000 | $1.39M | EDGAR |
| 2024-03-08 | STTK | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.